Tirzepatide, a flagship dual-target GLP-1/GIP peptide API, is a core active pharmaceutical ingredient for next-generation metabolic therapeutics, supporting the development and manufacture of formulations for glycemic control and weight management. Manufactured using a proprietary segmented peptide synthesis process, the product achieves a purity of ≥99.5%. Impurity profiles are strictly controlled in accordance with ICH and pharmacopeial quality standards, ensuring outstanding batch-to-batch consistency and highly stable biological activity.
Produced under standardized GMP-compliant manufacturing conditions, the product is manufactured at stable kilogram-scale capacity and supports customized packaging. It is supplied with a complete Certificate of Analysis (COA) and Drug Master File (DMF) documentation to meet regulatory submission requirements for pharmaceutical companies worldwide. The intact long-acting peptide structure fully preserves dual GLP-1/GIP biological activity, enabling sustained glycemic control and long-lasting weight reduction. Tirzepatide serves as a high-quality, compliant active pharmaceutical ingredient for the development of innovative metabolic therapeutics.